Tookad
What Tookad is used for
Tookad is indicated as monotherapy for adult patients with previously untreated, unilateral, low risk, adenocarcinoma of the prostate with a life expectancy … (the exact criteria are in the official EMA product information).
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Tookad
- Active substance
- padeliporfin
- Disease area
- Prostatic Neoplasms
- Medicine group
- Antineoplastic agents
- ATC code
- L01XD07
- Marketing authorisation holder
- STEBA Biotech S.A
- Authorised in the EU since
- 2017
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Tookad used for?
Tookad is indicated as monotherapy for adult patients with previously untreated, unilateral, low risk, adenocarcinoma of the prostate with a life expectancy … (the exact criteria are in the official EMA product information).
What is the active substance in Tookad?
Tookad contains padeliporfin.
Who makes Tookad?
The EU marketing authorisation holder is STEBA Biotech S.A.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU